TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9035263

Group type: EXPERIMENTAL
Intervention: sweet soft drink
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: filtered tap water
Number of subjects: 60

Group type: COMPARATOR
Intervention: nothing
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: palatable sweet food (chocolate-chip cookies)
Number of subjects: 60

Group type: COMPARATOR
Intervention: unpalatable food (black olives)
Number of subjects: 60

Group type: COMPARATOR
Intervention: neutral food (rice cakes)
Number of subjects: 60
Study: 8067602

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (studies not supporting vitamin C)
Number of subjects: 0
Study: 3312207

Group type: EXPERIMENTAL
Intervention: Cefamandole (five doses)
Number of subjects: 717

Group type: COMPARATOR
Intervention: Single preoperative dose of cefamandole
Number of subjects: 717
Study: 29610513

Group type: EXPERIMENTAL
Intervention: Preventive saline irrigation of the bile duct (PSIB) after stone removal
Number of subjects: 148

Group type: COMPARATOR
Intervention: Non-preventive saline irrigation (non-PSIB)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: PSIB
Number of subjects: 148

Group type: COMPARATOR
Intervention: PSIB and non-PSIB
Number of subjects: 148
Study: 27432017

Group type: EXPERIMENTAL
Intervention: Hospital-to-community medication records scheme
Number of subjects: 124

Group type: COMPARATOR
Intervention: Current level of hospital-to-community liaison (Control)
Number of subjects: 124
Study: 24094767

Group type: EXPERIMENTAL
Intervention: ALN-PCS (0.400 mg/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 23745954

Group type: EXPERIMENTAL
Intervention: Genuair
Number of subjects: 105

Group type: COMPARATOR
Intervention: HandiHaler
Number of subjects: 105
Study: 20189610

Group type: EXPERIMENTAL
Intervention: ghrelin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GHRP-6
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GHRH
Number of subjects: 18
Study: 17398083

Group type: EXPERIMENTAL
Intervention: 5%M+70%E/T‐gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5%M/T‐gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: 70%E/T‐gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: T‐gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: EMLA cream
Number of subjects: 0
Study: 11955535

Group type: EXPERIMENTAL
Intervention: Regimen A: zidovudine plus lamivudine starting at 36 weeks' gestation, followed by oral intrapartum dosing and by 7 days' postpartum dosing of mothers and infants.
Number of subjects: 1797

Group type: EXPERIMENTAL
Intervention: Regimen B: as regimen A, but without the prepartum component.
Number of subjects: 1797

Group type: EXPERIMENTAL
Intervention: Regimen C: intrapartum zidovudine and lamivudine only.
Number of subjects: 1797

Group type: COMPARATOR
Intervention: Placebo group.
Number of subjects: 1797
Study: 9848308

Group type: EXPERIMENTAL
Intervention: Endothelial nitric oxide synthase (eNOS) staining on spermatozoa
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control slides incubated with preabsorbed antibody or mouse immunoglobulin G
Number of subjects: 12
Study: 7527733

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ifosfamide
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Vincristine, Ifosfamide, and Peplomycin (VIP)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Doxorubicin, and CDDP (CAP)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ifosfamide, Doxorubicin, and CDDP (IAP)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Etoposide, Doxorubicin, and CDDP (EAP)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Single agents plus VIP
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Chemotherapy regimens (all)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: PSA doubling time
Number of subjects: 64
Study: 2657058

Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg once daily
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg twice daily
Number of subjects: 22
Study: 1059513

Group type: EXPERIMENTAL
Intervention: Manual toothbrushes with instruction and motivation (Groups 2 and 3)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Electric toothbrush (Touch Tronic, Teledyne Aqua Tec) with instruction and motivation (Group 4)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 123
Study: 30784127

Group type: EXPERIMENTAL
Intervention: Sleep hygiene education and reflexology
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 167
Study: 27748620

Group type: EXPERIMENTAL
Intervention: CCT plus availability of EI in the community (T1)
Number of subjects: 1113

Group type: EXPERIMENTAL
Intervention: CCT plus promotion of the EI program by the CCT program (T2)
Number of subjects: 1113

Group type: COMPARATOR
Intervention: CCT only (T0)
Number of subjects: 1113
Study: 24740588

Group type: EXPERIMENTAL
Intervention: 750 ml of fresh coffee brew
Number of subjects: 84

Group type: COMPARATOR
Intervention: 750 ml of water
Number of subjects: 84
Study: 23220425

Group type: EXPERIMENTAL
Intervention: Collapsing variant
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Not otherwise specified FSGS
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Tip variant
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Tip or collapsing variants
Number of subjects: 138
Study: 21895503

Group type: EXPERIMENTAL
Intervention: Metal-backed (MB) tibial components
Number of subjects: 9

Group type: COMPARATOR
Intervention: All-polyethylene (AP) tibial components
Number of subjects: 9
Study: 19951555

Group type: EXPERIMENTAL
Intervention: Glutamine-enriched enteral nutrition (0.5 g x kg(‐1) x d(‐1))
Number of subjects: 33
Study: 17116184

Group type: EXPERIMENTAL
Intervention: Conventional therapy plus Sweet Talk
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy and Sweet Talk
Number of subjects: 126

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 126
Study: 15084240

Group type: EXPERIMENTAL
Intervention: Red clover-derived isoflavone supplement (26 mg biochanin A, 16 mg formononetin, 1 mg genistein, 0.5 mg daidzein)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Red clover-derived isoflavone supplement
Number of subjects: 205
Study: 12396863

Group type: EXPERIMENTAL
Intervention: Median sensory nerve conduction velocity (SNCV) from digit 1 to wrist
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Median SNCV D/P ratio from palm to digit 3/palm to wrist
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Median SNCV digit 1 to wrist
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Median SNCV D/P ratio
Number of subjects: 213
Study: 9377115

Group type: EXPERIMENTAL
Intervention: Carbinoxamine-pseudoephedrine (Group A)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Astemizole-pseudoephedrine (Group B)
Number of subjects: 48
Study: 8321577

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (25 mg)
Number of subjects: 0
Study: 31328535

Group type: EXPERIMENTAL
Intervention: Functional connectivity MRI (fcMRI)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Multimodal CRF combining top 100 variables from each modality
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Multimodal CRF combining 19 top variables reaching >67% accuracy
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Multimodal CRF with reduced initial variables using a less granular region of interest scheme
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Random selection of 100 variables per modality
Number of subjects: 93
Study: 29205592

Group type: EXPERIMENTAL
Intervention: Dietary guidance to restrict polyphenol-rich foods
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (normal pregnancies)
Number of subjects: 75
Study: 26301385

Group type: EXPERIMENTAL
Intervention: Enthesis‐Dextrose
Number of subjects: 73

Group type: COMPARATOR
Intervention: Enthesis‐Saline
Number of subjects: 73

Group type: COMPARATOR
Intervention: Superficial‐Saline
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 73
Study: 24760656

Group type: EXPERIMENTAL
Intervention: OLM/AML/HCTZ 20/5/12.5 mg
Number of subjects: 2509

Group type: EXPERIMENTAL
Intervention: OLM/AML/HCTZ 40/5/12.5 mg
Number of subjects: 2509

Group type: EXPERIMENTAL
Intervention: OLM/AML/HCTZ 40/5/25 mg
Number of subjects: 2509

Group type: EXPERIMENTAL
Intervention: OLM/AML/HCTZ 40/10/12.5 mg
Number of subjects: 2509

Group type: EXPERIMENTAL
Intervention: OLM/AML/HCTZ 40/10/25 mg
Number of subjects: 2509
Study: 22175654

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 20026953

Group type: EXPERIMENTAL
Intervention: Inhomogeneous static magnetic field (SMF, 0 to 192 mT peak‐to‐peak magnetic flux density and 19 T/m lateral gradient) exposure for 30 minutes
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sham exposure (placebo)
Number of subjects: 59
Study: 18446025

Group type: EXPERIMENTAL
Intervention: Sugar-free gum containing 54 mg CPP-ACP
Number of subjects: 2720

Group type: COMPARATOR
Intervention: Control sugar-free gum without CPP-ACP
Number of subjects: 2720
Study: 17309715

Group type: EXPERIMENTAL
Intervention: Nerve stimulator-guided occipital nerve blockade
Number of subjects: 50

Group type: COMPARATOR
Intervention: Preservative-free normal saline (control)
Number of subjects: 50
Study: 12692482

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PTSD group
Number of subjects: 30
Study: 10749610

Group type: EXPERIMENTAL
Intervention: Laparoscopic resection (n = 17)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Open resection (n = 17)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 8958892

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms twice daily (n = 22)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms twice daily
Number of subjects: 31
Study: 1311648

Group type: EXPERIMENTAL
Intervention: Human-alpha atrial natriuretic factor (1-28) at a dose of 1.2 pmol min-1 kg-1
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3004088

Group type: EXPERIMENTAL
Intervention: 0.20 mg kg‐1 etomidate
Number of subjects: 19

Group type: COMPARATOR
Intervention: 3.15 mg kg‐1 thiopental
Number of subjects: 19
Study: 30206045

Group type: EXPERIMENTAL
Intervention: Post-transplant complications before day 100 (including relapse, lack of platelet recovery, grade-II acute GVHD, grade-III/IV acute GVHD)
Number of subjects: 784
Study: 29619605

Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Meloxicam
Number of subjects: 14
Study: 27824979

Group type: EXPERIMENTAL
Intervention: Immediate loading with a nonoccluding temporary crown within 24 hours after implant placement
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional loading according to a two-stage procedure after 3 months
Number of subjects: 62
Study: 24398317

Group type: EXPERIMENTAL
Intervention: Nigella Sativa oil (NSO)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution (ISCS)
Number of subjects: 42
Study: 22800984

Group type: EXPERIMENTAL
Intervention: Interview-Group (IG)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Non-Interview Group (NIG)
Number of subjects: 109
Study: 20424539

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study: 17478034

Group type: EXPERIMENTAL
Intervention: Propionyl L‐carnitine (PLC) alone (2 g/d)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Propionyl L‐carnitine (PLC) plus sildenafil (50 mg/d twice weekly)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sildenafil alone (50 mg/d twice weekly)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 15620433

Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 mg per day for 12 weeks)
Number of subjects: 125
Study: 12015683

Group type: EXPERIMENTAL
Intervention: GA combined with retrobulbar block (group B)
Number of subjects: 75

Group type: COMPARATOR
Intervention: General anaesthesia (GA) alone (group A)
Number of subjects: 75

Group type: COMPARATOR
Intervention: GA combined with peribulbar block (group C)
Number of subjects: 75
Study: 10623334

Group type: EXPERIMENTAL
Intervention: 20 micrograms of procaterol with large-volume spacer
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 20 micrograms of procaterol with small-volume spacer
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 50 micrograms of procaterol with MDI alone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 50 micrograms of procaterol with small-volume spacer
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 50 micrograms of procaterol with large-volume spacer
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Lower procaterol dose via large-volume spacer
Number of subjects: 14
Study: 7800305

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 1081

Group type: COMPARATOR
Intervention: Control group (no hormone replacement therapy)
Number of subjects: 1081
Study: 1983370

Group type: EXPERIMENTAL
Intervention: Silymarin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Amino‐imidazole‐carboxamide‐phosphate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 570272

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Naltrexone 100 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31789898

Group type: EXPERIMENTAL
Intervention: Ropivacaine 10 mg in 2.5 ml saline (4 mg/ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ropivacaine 10 mg in 5 ml saline (2 mg/ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ropivacaine 10 mg in 10 ml saline (1 mg/ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ropivacaine 10 mg in 15 ml saline (0.67 mg/ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ropivacaine 10 mg in 20 ml saline (0.5 mg/ml)
Number of subjects: 60
Study: 31520895

Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Combined RE and AE (CE)
Number of subjects: 406

Group type: COMPARATOR
Intervention: No exercise control group
Number of subjects: 406
Study: 28577580

Group type: EXPERIMENTAL
Intervention: Uncertain threat (participants were told they would flip a coin to determine if they would give a speech)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Certain threat (participants were told they would give a speech)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Both uncertain and certain threat conditions
Number of subjects: 79
Study: 25681448

Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DMF) 240 mg twice daily (BID)
Number of subjects: 1417

Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DMF) 240 mg three times daily (TID)
Number of subjects: 1417

Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DMF)
Number of subjects: 1417

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1417

Group type: COMPARATOR
Intervention: Subcutaneous glatiramer acetate 20 mg once daily (active reference comparator)
Number of subjects: 1417
Study: 23975067

Group type: EXPERIMENTAL
Intervention: Small-group training
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Web-based training
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study: 21277255

Group type: EXPERIMENTAL
Intervention: ramelteon 4 or 8 mg, titrated up to 16 mg if necessary for 24 weeks
Number of subjects: 190
Study: 19071061

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 1076

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 1076
Study: 17257711

Group type: EXPERIMENTAL
Intervention: 10 hours of didactic instruction and an 8-week perinatal clinical rotation
Number of subjects: 273

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 273
Study: 12871873

Group type: EXPERIMENTAL
Intervention: FSH priming (75 IU rFSH for 6 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-FSH priming (no FSH stimulation)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: FSH priming
Number of subjects: 60
Study: 11189538

Group type: EXPERIMENTAL
Intervention: Topical hyperbaric oxygen at 1.004 to 1.013 atmospheres (THOT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard wound care (SWC)
Number of subjects: 40
Study: 9362185

Group type: EXPERIMENTAL
Intervention: tinidazole 500 mg b.i.d.
Number of subjects: 113

Group type: COMPARATOR
Intervention: tetracycline 500 mg b.i.d.
Number of subjects: 113
Study: 1550521

Group type: EXPERIMENTAL
Intervention: 2 g ceftriaxone and 1 g metronidazole
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: 2 g ceftriaxone
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: 1 g cefazolin and 1 g metronidazole
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 280
Study: 3084176

Group type: EXPERIMENTAL
Intervention: Pinaverium bromide
Number of subjects: 0
Study: 30649613

Group type: EXPERIMENTAL
Intervention: CD HORIZON BalanC rod
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: S4 Dynamic rod
Number of subjects: 56
Study: 30943550

Group type: EXPERIMENTAL
Intervention: TTA Rapid
Number of subjects: 26

Group type: COMPARATOR
Intervention: TPLO
Number of subjects: 26
Study: 28885365

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation plus EMG-biofeedback therapy
Number of subjects: 103

Group type: COMPARATOR
Intervention: Swallowing function training (Control)
Number of subjects: 103
Study: 25005717

Group type: EXPERIMENTAL
Intervention: Intermittent phototherapy (IPT) with 12 h on and 12 h off cycles
Number of subjects: 75

Group type: COMPARATOR
Intervention: Continuous phototherapy (CPT)
Number of subjects: 75
Study: 23266209

Group type: EXPERIMENTAL
Intervention: High-dose DHA (100 mg/kg/day for the first month and 1g per day thereafter for 12 months)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (germ oil)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: High-dose DHA
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 21847583

Group type: EXPERIMENTAL
Intervention: LDL from obese metabolic syndrome patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LDL from type 2 diabetic patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control LDL from volunteers
Number of subjects: 30
Study: 19548163

Group type: EXPERIMENTAL
Intervention: Flaxseed gum (5 g) incorporated in wheat flour chapattis, consumed daily for 3 months.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group consumed identical diet without flaxseed gum.
Number of subjects: 60
Study: 16680932

Group type: EXPERIMENTAL
Intervention: Fexofenadine hydrochloride (60 mg) pretreatment 2 hours before immunization injection
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (no pretreatment)
Number of subjects: 134
Study: 15571443

Group type: EXPERIMENTAL
Intervention: Contingent voucher ($100)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Noncontingent voucher ($100)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 211
Study: 11681649

Group type: EXPERIMENTAL
Intervention: Jaszczak's method
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Factor analysis of dynamic sequences (FADS)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Uniform attenuation correction (UAC)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Broad-beam attenuation correction
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Narrow-beam inhomogeneous tissue attenuation correction
Number of subjects: 4
Study: 9644285

Group type: EXPERIMENTAL
Intervention: Memory requirement (remembering the precue)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continually available precue
Number of subjects: 0
Study: 8169755

Group type: EXPERIMENTAL
Intervention: High-dose RSV immune globulin (750 mg/kg, 15 ml/kg)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Low-dose RSV immune globulin (150 mg/kg, 3 ml/kg)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Control group (no RSVIG)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: High-dose RSV immune globulin
Number of subjects: 249
Study: 3275861

Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg/d)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (500 mg lactose/d)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Terbutaline (15 mg/d)
Number of subjects: 7
Study: 29064335

Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg
Number of subjects: 2200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2200
Study: 27322354

Group type: EXPERIMENTAL
Intervention: QIVc
Number of subjects: 2680

Group type: COMPARATOR
Intervention: TIV1c
Number of subjects: 2680

Group type: COMPARATOR
Intervention: TIV2c
Number of subjects: 2680
Study: 24287166

Group type: EXPERIMENTAL
Intervention: 200 mg modafinil
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 23224510

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (AMP) 10 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (AMP) 20 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Δ(9)-tetrahydrocannabinol (THC) 7.5 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Δ(9)-tetrahydrocannabinol (THC) 15 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 22078433

Group type: EXPERIMENTAL
Intervention: Edwards SAPIEN transcatheter heart valve
Number of subjects: 36
Study: 19380451

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 139

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Letrozole plus Zoledronic acid
Number of subjects: 139
Study: 16300823

Group type: EXPERIMENTAL
Intervention: Hygiene program including educational program and environmental changes
Number of subjects: 1029

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 1029